Evaluation of diagnostic methods for the detection of cytomegalovirus in recipients of allogeneic stem cell transplants
| Autor: | Wolfgang Preiser, Susanne Bräuninger, Holger F. Rabenau, Susanne Franck, Rainer Schwerdtfeger, Hans Wilhelm Doerr, Jeremy A. Garson, N S Brink, Ursula Ayliffe |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Human cytomegalovirus
Adult Male Adolescent Congenital cytomegalovirus infection Cytomegalovirus medicine.disease_cause Polymerase Chain Reaction Herpesviridae Viral Matrix Proteins Betaherpesvirinae Virology medicine Humans Transplantation Homologous Antigens Viral Whole blood biology Hematopoietic Stem Cell Transplantation virus diseases Middle Aged medicine.disease biology.organism_classification Phosphoproteins NASBA Infectious Diseases Real-time polymerase chain reaction medicine.anatomical_structure Immunology Cytomegalovirus Infections DNA Viral Female Bone marrow Reagent Kits Diagnostic Nucleic Acid Amplification Techniques |
| Zdroj: | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 20(1-2) |
| ISSN: | 1386-6532 |
| Popis: | Background: Although several diagnostic methods are available for the surveillance of patients at risk of human cytomegalovirus (CMV) infection and disease, little data is available on their comparative performances in the diagnostic setting. Objectives: To compare different assays for CMV detection, especially assays based on (quantitative) DNA and mRNA detection. Study design: Eight allogeneic bone marrow and stem cell transplant recipients at high risk for developing CMV disease (donor CMV-negative, recipient positive) were regularly tested for 7–20 weeks post-transplant by spin-amplification rapid culture from urine (viruria), antigenemia (pp65 assay), pp67 mRNA in whole blood (NASBA), and CMV DNA both qualitatively (in-house PCR, whole blood) and quantitatively (in-house PCR, plasma; Cobas Amplicor™ CMV Monitor Test, plasma and whole blood; Hybrid Capture™, whole blood). Results: Four patients (50%) suffered CMV reactivation during follow-up. Out of 104 sample dates, 41 (39.4%) yielded a positive CMV result in at least one assay. Out of the 28 samples tested by all assays, the highest percentage of positive results was obtained with the in-house quantitative PCR (60.7%), followed by the Hybrid Capture™ system (39.3%), the Cobas Amplicor™ CMV Monitor Test, plasma version (35.7%), the Cobas Amplicor™ CMV Monitor Test, whole blood version (32.1%), in-house qualitative PCR (28.6%), and the mRNA assay (21.4%). Viruria was positive in one sample and pp65 antigenemia was found in two samples. Conclusions: Despite a considerable incidence of CMV reactivations, pre-emptive anti-CMV chemotherapy prevented the development of CMV disease with the exception of one case. The molecular assays had superior sensitivity to conventional ones. The antigenemia assay proved unsuitable for the surveillance of hematological transplant patients. However, none of the tests recognized all timepoints with CMV reactivation. Further comparative studies are needed to determine their respective diagnostic values. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect